|
|
||||||||
1 Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan University Shanghai Medical College, 413 Zhaozhou Road, Shanghai 200011, China
2 Department of Obstetrics and Gynecology, Hainan Medical College, The Affiliated Hospital, Haikou 570102, China
(Requests for offprints should be addressed to D-J Li; Email: djli{at}shmu.edu.cn)
(Y-D Wang is now at Department of Obstetrics and Gynecology, the Sixth Peoples Hospital, Shanghai Jiaotong University, Shanghai 200233, China)
Dehydroepiandrosterone (DHEA) may be a promising agent for postmenopausal osteoporosis (PMO), but its mechanism to modulate osteoblasts (OBs) is yet to be explained. To elucidate the effects of DHEA treatment on the ovariectomized (OVX) mice and its mechanisms, we evaluated the morphology of mice bone tissue and expression of proliferating cell nuclear antigen (PCNA) in the vertebrae-derived OB after having treated the OVX animals with DHEA. The results showed that DHEA administration increased the expression of PCNA in OB and changed the bone tissue morphometry of the PMO model. To further investigate this mechanism, the OB was isolated from neonatal mice calvariae by the enzyme-digested assay, exposed to DHEA, and then analyzed for ultrastructure, DNA content, early apoptotic cells, and phosphorylation of extracellular signal-regulated kinase 1/2. It was found that DHEA promoted proliferation and inhibited apoptosis of OB significantly, via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor, suggesting that it may exert roles via a DHEA-specific receptor directly, not by way of conversion to androgens or estrogens.
This article has been cited by other articles:
![]() |
E. P Weiss, K. Shah, L. Fontana, C. P Lambert, J. O Holloszy, and D. T Villareal Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1459 - 1467. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |